Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model

Hrkach, 2012, Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile, Sci. Transl. Med., 4, 10.1126/scitranslmed.3003651 Ara, 2014, An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells, Biomaterials, 35, 7110, 10.1016/j.biomaterials.2014.04.087 Kang, 2010, A liposome-based nanostructure for aptamer directed delivery, Chem. Commun. (Camb.), 46, 249, 10.1039/B916911C Blanco, 2014, Emerging nanotherapeutic strategies in breast cancer, Breast, 23, 10, 10.1016/j.breast.2013.10.006 Hatakeyama, 2013, The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors, Biol. Pharm. Bull., 36, 892, 10.1248/bpb.b13-00059 Hama, 2015, Overcoming the polyethylene glycol dilemma via pathological environment-sensitive change of the surface property of nanoparticles for cellular entry, J. Control. Release, 206, 67, 10.1016/j.jconrel.2015.03.011 Zhang, 2015, [PEG dilemma for liposomes and its solving approaches], Yao Xue Xue Bao, 50, 252 Bertrand, 2014, Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology, Adv. Drug Deliv. Rev., 66, 2, 10.1016/j.addr.2013.11.009 Yameen, 2014, Insight into nanoparticle cellular uptake and intracellular targeting, J. Control. Release, 190, 485, 10.1016/j.jconrel.2014.06.038 Sapra, 2003, Ligand-targeted liposomal anticancer drugs, Prog. Lipid Res., 42, 439, 10.1016/S0163-7827(03)00032-8 Forssen, 1998, Ligand-targeted liposomes, Adv. Drug Deliv. Rev., 29, 249, 10.1016/S0169-409X(97)00083-5 Xiang, 2015, Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine, Theranostics, 5, 23, 10.7150/thno.10202 Ellington, 1990, In vitro selection of RNA molecules that bind specific ligands, Nature, 346, 818, 10.1038/346818a0 Wang, 2014, Current progress of aptamer-based molecular imaging, J. Nucl. Med., 55, 353, 10.2967/jnumed.113.126144 Gopinath, 2007, Methods developed for SELEX, Anal. Bioanal. Chem., 387, 171, 10.1007/s00216-006-0826-2 Farokhzad, 2006, Nanoparticle-aptamer bioconjugates for cancer targeting, Expert Opin. Drug Deliv., 3, 311, 10.1517/17425247.3.3.311 Farokhzad, 2004, Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells, Cancer Res., 64, 7668, 10.1158/0008-5472.CAN-04-2550 Dua, 2011, Nucleic acid aptamers targeting cell-surface proteins, Methods, 54, 215, 10.1016/j.ymeth.2011.02.002 Cao, 2009, Reversible cell-specific drug delivery with aptamer-functionalized liposomes, Angew. Chem. Int. Ed. Engl., 48, 6494, 10.1002/anie.200901452 Liu, 2014, Aptamer-conjugated nanomaterials for specific cancer cell recognition and targeted cancer therapy, NPG Asia Mater., 6, e95, 10.1038/am.2014.12 Li, 2014, Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas, Biomaterials, 35, 3840, 10.1016/j.biomaterials.2014.01.019 Xing, 2013, Selective delivery of an anticancer drug with aptamer-functionalized liposomes to breast cancer cells in vitro and in vivo, J. Mater. Chem. B, 1, 5288, 10.1039/c3tb20412j Mann, 2011, Thioaptamer conjugated liposomes for tumor vasculature targeting, Oncotarget, 2, 298, 10.18632/oncotarget.261 Moosavian, 2015, Development of RNA aptamers as molecular probes for HER2+ breast cancer study using cell-SELEX, Iran. J. Basic Med. Sci., 18, 576 Liu, 2012, Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro, J. Transl. Med., 10, 148, 10.1186/1479-5876-10-148 Hsieh, 2007, Targeting HER proteins in cancer therapy and the role of the non-target HER3, Br. J. Cancer, 97, 453, 10.1038/sj.bjc.6603910 Amin, 2013, Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas, Int. J. Pharm., 458, 324, 10.1016/j.ijpharm.2013.10.018 Klibanov, 2010, Long-circulating strerically protected liposomes, 231 Gu, 2009, Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery, Methods Mol. Biol., 544, 589, 10.1007/978-1-59745-483-4_37 Shahin, 2013, Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin, Cancer Lett., 334, 284, 10.1016/j.canlet.2012.10.007 Sayari, 2014, MUC1 aptamer conjugated to chitosan nanoparticles, an efficient targeted carrier designed for anticancer SN38 delivery, Int. J. Pharm., 473, 304, 10.1016/j.ijpharm.2014.05.041 Horowitz, 1992, In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release, Biochim. Biophys. Acta (BBA)—Biomembr., 1109, 203, 10.1016/0005-2736(92)90084-Y Huang, 2009, Disterolphospholipids: nonexchangeable lipids and their application to liposomal drug delivery, Angew. Chem. Int. Ed. Engl., 48, 4146, 10.1002/anie.200900111 Huang, 2008, Sterol-modified phospholipids: cholesterol and phospholipid chimeras with improved biomembrane properties, J. Am. Chem. Soc., 130, 15702, 10.1021/ja8065557 Schluep, 2006, Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models, Clin. Cancer Res., 12, 1606, 10.1158/1078-0432.CCR-05-1566 Maeda, 2000, Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review, J. Control. Release, 65, 271, 10.1016/S0168-3659(99)00248-5 Barenholz, 2012, Doxil(R)—the first FDA-approved nano-drug: lessons learned, J. Control. Release, 160, 117, 10.1016/j.jconrel.2012.03.020 Sanna, 2014, Targeted therapy using nanotechnology: focus on cancer, Int. J. Nanomed., 9, 467 Allen, 2007, Pharmacokinetics and Biopharmaceutics of Lipid-based Drug Formulations, 49 Garcia, 1998, A phase II study of Doxil (liposomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas, Ann. Oncol., 9, 1131, 10.1023/A:1008439013169 Halford, 2001, A phase II study evaluating the tolerability and efficacy of CAELYX (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic carcinoma, Ann. Oncol., 12, 1399, 10.1023/A:1012522120294 Muggia, 2002, Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a gynecologic oncology group study, J. Clin. Oncol., 20, 2360, 10.1200/JCO.2002.08.171 Hong, 1999, Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?, Clin. Cancer Res., 5, 3645 Ogawara, 2009, In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: involvement of cytotoxic effect on vascular endothelial cells, J. Control. Release, 133, 4, 10.1016/j.jconrel.2008.09.008 Jabr-Milane, 2008, Multi-functional nanocarriers to overcome tumor drug resistance, Cancer Treat. Rev., 34, 592, 10.1016/j.ctrv.2008.04.003 Zhao, 2013, A simple way to enhance Doxil® therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer, J. Control. Release, 168, 61, 10.1016/j.jconrel.2013.02.026 Levy-Nissenbaum, 2008, Nanotechnology and aptamers: applications in drug delivery, Trends Biotechnol., 26, 442, 10.1016/j.tibtech.2008.04.006 Farokhzad, 2006, Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo, Proc. Natl. Acad. Sci. U. S. A., 103, 6315, 10.1073/pnas.0601755103 Kirpotin, 1997, Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro, Biochemistry, 36, 66, 10.1021/bi962148u Arabi, 2015, Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin, J. Control. Release, 220, 275, 10.1016/j.jconrel.2015.10.044 Xiang, 2015, Superior Performance of Aptamer in Tumor Penetration over Antibody: Implication of Aptamer-Based Theranostics in Solid Tumors, Theranostics, 5, 1083, 10.7150/thno.11711 Forbes, 2015, Inside-outside self-assembly of light-activated fast-release liposomes, Phys. Chem. Chem. Phys., 17, 15569, 10.1039/C4CP05881J Baek, 2014, RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo, J. Control. Release, 196, 234, 10.1016/j.jconrel.2014.10.018 Jalali, 2012, Induction of tumor-specific immunity by multi-epitope rat HER2/neu-derived peptides encapsulated in LPD Nanoparticles, Nanomedicine, 8, 692, 10.1016/j.nano.2011.09.010